biostudies-literatureSanyal AJNCATS NIH HHSNIDDK NIH HHSNHLBI NIH HHS693-703https://www.ebi.ac.uk/biostudies/studies/S-EPMC10165617biostudies-literatureUnknown78(4)<h4>Background & aims</h4>Despite recent progress, non-invasive tests for the diagnostic assessment and monitoring of non-alcoholic fatty liver disease (NAFLD) remain an unmet need. Herein, we aimed to identify diagnostic signatures of the key histological features of NAFLD.<h4>Methods</h4>Using modified-aptamer proteomics, we assayed 5,220 proteins in each of 2,852 single serum samples from 636 individuals with histologically confirmed NAFLD. We developed and validated dichotomized protein-phenotype models to identify clinically relevant severities of steatosis (grade 0 vs. 1-3), hepatocellular ballooning (0 vs. 1 or 2), lobular inflammation (0-1 vs. 2-3) and fibrosis (stages 0-1 vs. 2-4).<h4>Results</h4>The AUCs of the four protein models, based on 37 analytes (18 not previously linked tJournal of hepatologyDefining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.PMC10165617UL1 TR000058R01 DK121378UL1 TR001442UL1 TR000436UL1 TR000439U01 DK061718U01 DK061737U01 DK061738P01 HL147835U24 DK061730R01 DK124318UL1 TR000100UL1 TR000006U01 DK061732U01 DK061713UL1 TR000004U01 DK061734UL1 TR000423U01 DK061731UL1 TR000448U01 DK061730U01 DK130190U01 DK061728R01 DK106419P30 DK120515Williams SAKowdley KVTonascia JWilliams JBiegel HChalasani NDiehl AMKleiner DEAlexander LYates KPOstroff RNeuschwander-Tetri BALoomba RSanyal AJLavine JEBehling CJia YDasarathy SHameed BKarpen SJfalseDefining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.<h4>Background & aims</h4>Despite recent progress, non-invasive tests for the diagnostic assessment and monitoring of non-alcoholic fatty liver disease (NAFLD) remain an unmet need. Herein, we aimed to identify diagnostic signatures of the key histological features of NAFLD.<h4>Methods</h4>Using modified-aptamer proteomics, we assayed 5,220 proteins in each of 2,852 single serum samples from 636 individuals with histologically confirmed NAFLD. We developed and validated dichotomized protein-phenotype models to identify clinically relevant severities of steatosis (grade 0 vs. 1-3), hepatocellular ballooning (0 vs. 1 or 2), lobular inflammation (0-1 vs. 2-3) and fibrosis (stages 0-1 vs. 2-4).<h4>Results</h4>The AUCs of the four protein models, based on 37 analytes (18 not previously linked t2023-01-01T00:00:00Z2023 Apr2026-05-28T08:22:08.55Z2025-04-05T21:09:33.608ZS-EPMC101656173652823710.1016/j.jhep.2022.11.029